A part of Watch Media

MedWatchSaturday4 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
24/06/2021at 14:26

Lilly gets sought-after FDA designation for Alzheimer's candidate

The US FDA is accompanying the recent approval of Biogen's Alzheimer's treatment with a breakthrough therapy designation for another potential treatment of the disease.
Photo: Mike Blake/REUTERS / X00030
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Eli Lilly's drug candidate donanemab treating Alzheimer's disease has received breakthrough therapy status at the US Food and Drug Administration, according to a press release from Eli Lilly.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Nu mangler kun en endelig vedtagelse i EU-Parlamentet, før lovforslag om at udskyde deadlines for nye krav til medicinsk udstyr. er en realitet. | Foto: Thomas Borberg/Ritzau Scanpix
Medtech

Another hurdle overcome in delaying MDR deadline

EU member countries have voted unanimously to adopt an EU Commission proposal to stagger the implementation of the new Medical Device Regulation. Now, only the EU Parliament’s vote remains. 
  • Asensus Surgical wins CE Mark for intelligent surgical unit under MDR rules
  • EU Commission to give more time for MDR transition

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology
Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

For subscribers

Foto: Coloplast/pr
Medtech

Coloplast launches male catheter featuring new technology

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast's bottom line disappoints in otherwise strong report

For subscribers

Further reading

Foto: Novo Nordisk / Pr
Pharma & biotech

Novo Nordisk CEO rakes in cash in record year

Being at the top of Denmark’s most valuable company is lucrative, Novo Nordisk reveals in its annual report – and Chief Executive Lars Fruergaard Jørgensen is making a killing there.

For subscribers

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology
Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

A male catheter is the Danish medtech company’s biggest launch in half a decade – and CFO Anders Lonning-Skovgaard expects the 12-month rollout to be nothing but smooth sailing.

For subscribers

Foto: Tidsvilde Stine/Ritzau Scanpix
Pharma & biotech

Novo Nordisk declared world's best place to work in 2022

The Best Places to Work organization has released its 2022 list of the best workplaces across the world, and Danish Novo Nordisk shines at the top.

For subscribers

Latest news

  • Top news from MedWatch this week – 3 Feb
  • Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps – 3 Feb
  • China accepts regulatory filing for ALK allergy tablet – 3 Feb
  • Another hurdle overcome in delaying MDR deadline – 3 Feb
  • Dupixent becomes ninefold blockbuster – 3 Feb
  • ALK forecasts lower growth in 2023 than strong 2022 result – 3 Feb
  • Unilabs and Siemens Healthineers enter million-euro strategic partnership – 3 Feb
  • Coloplast launches male catheter featuring new technology – 3 Feb
  • Novo Nordisk hopes to retain employees with share gift – 3 Feb
  • Coloplast's bottom line disappoints in otherwise strong report – 3 Feb
See all

Jobs

  • Application Manager

  • Commercial Director

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Clinical Operational Associate

  • Medical Advisor (Metabolism)

  • Experienced Patent Counsel

  • Sr. Director, Drug Safety Physician

  • Senior Clinical Project Manager

  • Supply Chain Manager

  • Application Manager

  • Regulatory Affairs Professional

See all jobs

Jobs

  • Application Manager

  • Commercial Director

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Clinical Operational Associate

  • Medical Advisor (Metabolism)

  • Experienced Patent Counsel

  • Sr. Director, Drug Safety Physician

  • Senior Clinical Project Manager

  • Supply Chain Manager

  • Application Manager

  • Regulatory Affairs Professional

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge